BIOBV logo

Biohit Oyj Stock Price

HLSE:BIOBV Community·€53.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

BIOBV Share Price Performance

€3.54
1.24 (53.91%)
€3.54
1.24 (53.91%)
Price €3.54

BIOBV Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with acceptable track record.

3 Risks
3 Rewards

Biohit Oyj Key Details

€14.3m

Revenue

€4.6m

Cost of Revenue

€9.6m

Gross Profit

€7.4m

Other Expenses

€2.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 11, 2026
0.15
67.49%
15.88%
0%
View Full Analysis

About BIOBV

Founded
1988
Employees
49
CEO
Jussi Hahtela
WebsiteView website
www.biohithealthcare.com

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vitamin D, a test for determination of 25-hydroxyvitamin D2 and D3; and BIOHIT Calprotectin test, a quantitative test that provides a reliable differentiation between inflammatory bowel diseases and irritable bowel syndrome. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; Gluten Immunogenic Peptides test; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. The company provides acetaldehyde-binding products, such as Acetium capsules for protection of stomach; Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. It also offers BIOHIT FAEX for the collection and handling of stool samples; and GP Reader NT, an automated instrument for the quantitative determination of various analytes in human samples, such as whole blood, plasma, or fecal samples by measuring fluorescence signals from lateral flow test cassettes. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Recent BIOBV News & Updates

Recent updates

No updates